Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference

Rhea-AI Summary

Caladrius Biosciences (Nasdaq: CLBS) announces that CEO David J. Mazzo will present at the 13th annual LD Micro Main Event on December 14, 2020, at 10:20 AM ET. This virtual conference occurs on December 14-15, hosted on Sequire's platform. The company focuses on developing innovative cellular therapies aimed at reversing diseases. Current candidates include HONEDRA® for critical limb ischemia, CLBS14 for refractory angina, CLBS16 for coronary microvascular dysfunction, and CLBS119 for COVID-19 related complications. For more details, visit www.caladrius.com.

BASKING RIDGE, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will be presenting at the 13^th annual LD Micro Main Event investor conference on Monday, December 14, 2020 at 10:20 AM Eastern Time.

The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform. For more information on how to register, please visit ve.mysequire.com/.

View Caladrius Biosciences profile on LD Micro here: http://www.ldmicro.com/profile/CLBS

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients. For more information on the company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com

Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com

FAQ

When is Caladrius Biosciences' presentation at the LD Micro Main Event?

Caladrius Biosciences' presentation at the LD Micro Main Event is scheduled for December 14, 2020, at 10:20 AM ET.

What is the focus of Caladrius Biosciences?

Caladrius Biosciences is dedicated to developing cellular therapies designed to reverse diseases.

What are the current product candidates of Caladrius Biosciences?

Current product candidates include HONEDRA® for critical limb ischemia, CLBS14 for refractory angina, CLBS16 for coronary microvascular dysfunction, and CLBS119 for COVID-19 related lung damage.

Where can I find more information about Caladrius Biosciences?

More information can be found on their official website at www.caladrius.com.

How can I register for the LD Micro Main Event?

You can register for the LD Micro Main Event by visiting the Sequire Virtual Events platform at ve.mysequire.com.